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IntroductIon
Neuroinflammation accompanies several diseases with or 
without an immunological origin such as multiple sclerosis 
(MS), stroke, traumatic brain injury, Parkinson’s disease, and 
Alzheimer’s disease (Wyss-Coray, 2006; Rivest, 2009; Heneka 
et al., 2010; Kigerl et al., 2014). Such inflammatory response 
is generally referred to as sterile inflammation because mi-
crobial pathogens are not typically involved, but rather, the 
response is directed by damage-associated inflammatory in-
ducers. Sterile inflammation is linked to a plethora of inflam-
matory disorders within and outside of the central nervous 
system (CNS; Rock et al., 2010).
The nucleotide-binding leucine-rich repeat (LRR)–
containing (NLR; also known as NOD-like receptors) 
proteins have emerged as a key family of sensors and regu-
lators responding to pathogen-associated molecular patterns 
(PAMPs) generated by intracellular pathogen and damage- 
associated molecular patterns (DAMPs) produced under 
nonmicrobial inflammatory conditions (Strowig et al., 2012; 
Broderick et al., 2015; Guo et al., 2015; Broz and Dixit, 2016). 
There are >20 NLR genes in humans and >30 in mice. NLR 
genes encode cytoplasmic proteins with a tripartite domain 
structure consisting of a variable N-terminal effector domain, 
a central nucleotide-binding domain, and a variable number 
of C-terminal LRRs. The initial characterization of NLRs 
showed that many are expressed in cells that contribute to 
innate immunity such as monocytes, granulocytes, macro-
phages, and dendritic cells.
A subfamily of NLR proteins mediate the activation of 
caspase-1, which is referred to as inflammasome activation 
(Martinon et al., 2002). Multiple NLR proteins have been 
recognized as mediators of inflammasome activation by the 
sensing of stimuli (Khare et al., 2012). Some notable exam-
ples include NLRP1 (Boyden and Dietrich, 2006), NLRP3 
(Kanneganti et al., 2006; Mariathasan et al., 2006; Martinon 
et al., 2006; Sutterwala et al., 2006), NLRP6 (Anand et al., 
2012), NLRP7 (Khare et al., 2012), NLRP12 (Vladimer et 
al., 2012), NLRC4 (Zhao et al., 2011), NLRC5 (Davis et 
al., 2011; Triantafilou et al., 2013), and NAIP (NLR family 
apoptosis inhibitory protein; Kofoed and Vance, 2011; Zhao et 
al., 2011) or non-NLR proteins (e.g., AIM2; Bürckstümmer 
et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 
2009; Rathinam et al., 2010). Gene mutations in a key family 
member, NLRP3, lead to several autoinflammatory disorders 
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collectively referred to as the cryopyrin-associated periodic 
syndromes (Broderick et al., 2015). The association of muta-
tions in inflammasome NLR genes with autoinflammatory 
diseases underscores an important function of these genes in 
regulating inflammation in humans.
Among inflammasome NLRs, NLR family CARD 
(caspase recruitment domain)-containing 4 (NLRC4; ini-
tially named Ipaf; Poyet et al., 2001) is well studied and prob-
ably better understood in the context of bacterial infection. 
NLRC4 is a cytosolic sensor of flagellin produced by flagel-
lated pathogens such as Salmonella typhimurium, Legionella 
pneumophila (Amer et al., 2006), and the type III secretory 
system (T3SS) from gram-negative pathogens such as S. ty-
phimurium, Burkholderia pseudomallei, Escherichia coli, 
Shigella flexneri (Suzuki et al., 2007), and Pseudomonas aeru-
ginosa (Sutterwala et al., 2007).
Initial characterization of NLRC4 in human tissues 
and cell lines demonstrated its direct association with pro–
caspase-1 through CARD–CARD interactions (Geddes et al., 
2001; Poyet et al., 2001). This interaction causes autocatalytic 
processing of pro–caspase-1 to caspase-1 (Poyet et al., 2001). 
Activated caspase-1 can, in turn, cleave >70 substrates, includ-
ing IL-1β and IL-18 (Shao et al., 2007; Keller et al., 2008). A 
constitutively active NLRC4 causes autocatalytic processing 
of pro–caspase-1 leading to caspase-1–dependent apoptosis in 
transfected cells (Poyet et al., 2001). When an Nlrc4 gene de-
letion strain was examined, the physiological relevance of this 
protein showed specificity in caspase-1 activation and IL-1β 
release caused by S. typhimurium but not by the combina-
tion of ATP and LPS (Mariathasan et al., 2004). Because the 
NLRP3 inflammasome was later found to be activated by 
ATP and LPS, these results showed that NLRP3 and NLRC4 
are activated by different activators. However, NLRC4 was 
shown to recruit NLRP3 to the inflammasome complex 
during Salmonella infection (Qu et al., 2016), suggesting that 
the combined activity is critical to inflammasome activation.
Recent data indicate that the NAIP proteins recognize 
microbial pathogens and then recruit NLRC4 proteins to the 
inflammasome. Specifically, NAIP1 and NAIP2 recognize 
bacterial T3SS rod and needle proteins, whereas NAIP5 and 
NAIP6 recognize bacterial flagellin. Both sets of NAIP pro-
teins interact with the NLRC4 inflammasome in response 
to their respective bacterial ligands (Kofoed and Vance, 2011; 
Zhao et al., 2011; Halff et al., 2012; Rayamajhi et al., 2013; 
Yang et al., 2013). The use of cryoelectron microscopy has fur-
ther illuminated how NLRC4 is activated. It was found that 
one molecule of NAIP2 binding to bacterial PrgJ is sufficient 
to activate NLRC4, which undergoes a rotation shift, causing 
polymerization and recruitment of additional NLRC4 mol-
ecules into the complex (Hu et al., 2015; Zhang et al., 2015). 
A similar study of NAIP5/NLRC4 also shows a prominent 
rotation of the NLRC4 LRR domain upon NAIP5 interac-
tion with flagellin (Diebolder et al., 2015).
Although the role of NLRC4 in bacterial sensing is 
well studied, the role of NLRC4 in sterile inflammation 
where the inflammatory source is not microbial in nature re-
mains undefined. In experimental colitis, NLRC4 has been 
found to provide a protective role, although this finding is 
not uniformly reported and may be attributed to variable 
microbiomes because of institutional differences or strain of 
Nlrc4−/− mice used in the studies (Allen et al., 2010; Hu et al., 
2010; Carvalho et al., 2012). Colitis is not considered sterile 
inflammation because the inflammation associated with coli-
tis is thought to be significantly impacted by the gut micro-
biome (Elinav et al., 2011; Bauer et al., 2012). More recently, 
NLRC4 has been found to promote obesity-induced breast 
cancer, although the DAMPs that activate this pathway were 
not identified (Kolb et al., 2016).
Inflammation of the CNS is increasingly recognized 
as a key factor in a plethora of neurological diseases where 
neuroinflammation is believed to exacerbate demyelinating 
disease severity. Neuroinflammation may be attributed to 
lymphocytes and macrophage-myeloid cells associated with 
the immune system, as well as microglia and astrocytes within 
the brain parenchyma (Dong and Benveniste, 2001; Carson, 
2002). Extensive studies have linked the NLRP3 inflam-
masome to neurological disorders such as MS and Alzheimer’s 
disease (Halle et al., 2008; Heneka et al., 2013), whereas AIM2 
and NLRP1 have been linked to traumatic brain injury (de 
Rivero Vaccari et al., 2009; Adamczak et al., 2014). However, 
NLRC4 has not been extensively studied in these contexts.
In this study, we examine the role of lysophosphatidyl-
choline (LPC; also known as lysolecithin) as a DAMP rel-
evant to neuroinflammation. LPC, a major component of 
low-density lipoprotein, is generated by hydrolysis of phos-
phatidylcholine via phospholipase A2 (PLA2; Schilling et al., 
2004) under normal physiological conditions. Normally, LPC 
is rapidly metabolized or reacetylated; however, under patho-
logical conditions, there is increased activity of PLA2, leading 
to accumulation of LPC. Such an increase in PLA2 activity 
is seen in MS, ischemia, epilepsy, Alzheimer’s disease, schizo-
phrenia, and spinal cord injury (Farooqui et al., 2006). LPC is 
known to cause glial activation resulting in the transcription 
of proinflammatory cytokines (Sheikh and Nagai, 2011). LPC 
is also recognized as an inflammatory inducer that activates 
immune cells, but the underlying mechanism has not been 
extensively investigated (Kabarowski et al., 2002). With re-
spect to cytokines, LPC is known to activate microglia and 
lead to IL-1β release in a P2X7R-independent mechanism 
(Schilling et al., 2004; Stock et al., 2006). Moreover, PLA2 is 
known to contribute to demyelination and immune cell ac-
cumulation in Wallerian degeneration. LPC can enhance de-
myelination in brain spheroid cultures (Vereyken et al., 2009) 
and cause demyelination in several animal models (Waxman 
et al., 1979; Shikishima et al., 1985).
In this study, we find that LPC induces inflammasome 
activation in a process that is surprisingly dependent on both 
NLRP3 and NLRC4 through the canonical, but not the 
noncanonical, inflammasome pathway. We find significant 
NLRC4 expression during neuroinflammation, especially in 
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astrocytes in mice as well as in human demyelinating disease 
neurological specimens. The cuprizone mouse model of neu-
roinflammation and demyelination was used to analyze the 
roles of these proteins because the neurotoxicant cuprizone 
leads to robust microglial and astrocyte activation and accu-
mulation in major myelinated nerve tracts, such as the corpus 
callosum and cerebellar peduncles (Matsushima and Morell, 
2001), followed by the death of oligodendrocytes and demye-
lination (Liu et al., 2010). Disease is easily induced by admin-
istering cuprizone through the chow, follows a predictable 
time course, and generates reproducible pathology. Using this 
model, we show that NLRC4 and NLRP3 contribute sig-
nificantly to neuropathology and that deletion of these genes 
results in reduced neuroinflammation and demyelination.
reSuLtS
the inflammasome mediates LPc-induced IL-1β 
secretion in mouse BMdMs
We assessed inflammasome activation by molecules associ-
ated with CNS disease by analyzing LPC activity. To assess 
whether LPC could activate the inflammasome, we generated 
BMDMs from WT, Nlrp3−/−, Nlrc4−/−, Asc (apoptotic speck 
containing protein with a CARD)−/−, Casp1−/−, Il1b−/−, and 
Casp11−/− mice and primed these cells with LPS followed 
by LPC stimulation. Then, IL-1β release was quantified by 
ELI SA (Fig. 1, A–D) and immunoblotting (Fig. 2, A–D). In 
these experiments, cells were primed with LPS, which is a 
well-documented inducer of signal 1 of inflammasome ac-
tivation, inducing the transcription and translation of in-
flammasome components, such as pro–IL-1β, pro–caspase-1, 
and NLRP3. After LPS pretreatment, LPC was tested for 
signal 2 activity, which normally leads to caspase-1 and 
IL-1β maturation followed by secretion of IL-1β. A com-
bination of LPS and LPC caused significant IL-1β release 
in WT BMDMs (Fig.  1, A–D; and Fig.  2, A–D). However, 
IL-1β secretion in Nlrp3−/−, Nlrc4−/−, Asc−/−, Casp1−/−, and 
Il1b−/− BMDMs was reduced compared with WT controls 
but not in Casp11−/− BMDMs (Fig. 1, A–D; and Fig. 2, A–D). 
These results indicate that inflammasome-associated proteins 
NLRC4, NLRP3, caspase-1, and ASC mediate LPC-induced 
IL-1β secretion in BMDMs, whereas the noncanonical in-
flammasome-associated protein capase-11 is not involved. 
LPC-induced inflammasome activation was also inhibited by 
a caspase-1 inhibitor, YVAD (Z-Tyr-Val-Ala-Asp[OMe]-flu-
oromethylketone; Fig. 1 E and Fig. 2 E).
To further explore how NLRP3 might mediate 
LPC-induced IL-1β secretion in BMDMs, we pretreated WT 
BMDMs with inhibitors of intracellular NLRP3 agonists be-
fore LPC stimulation and measured IL-1β secretion by ELI 
SA (Fig. 1, F–K) and immunoblotting (Fig. 2, F–I). Inhibi-
tors of reactive oxygen species (ROS; NAC [N-acetyl-l-cys-
teine], MPG [N-(2-mercaptopropionyl)glycine], and APDC 
[(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid]) and 
mitochondrial ROS production (Mitotempo) did not signifi-
cantly reduce LPC-induced inflammasome activation (Fig. 1, 
F and G; and Fig. 2 F). Inhibitors of cathepsin B–mediated 
degradation (CA-074Me), K+ efflux (glyburide), and Ca2+ in-
flux (BAP TA, 2-APB, and U73122) reduced LPC-induced 
IL-1β secretion in BMDMs (Fig. 1, H–K; and Fig. 2, G–I). This 
suggests that LPC induction of IL-1β secretion in BMDMs is 
dependent on cathepsin B, Ca2+ influx, and K+ efflux.
With the observation that LPC induces IL-1β secretion 
in WT BMDMs, we examined whether NLRP3 and NLRC4 
are required for LPC-induced cell death. BMDMs were iso-
lated from WT, inflammasome-associated gene–deficient 
mice, and noncanonical inflammasome-associated gene–defi-
cient mice, LPS primed, and stimulated with increasing con-
centrations of LPC. Supernatants were collected, and lactate 
dehydrogenase (LDH) was measured to assess the level of cell 
death (Fig. S1). Although there was a decrease in LDH levels in 
Nlrp3−/−, Nlrc4−/−, Asc−/−, and Casp1−/− BMDMs compared 
with WT BMDMs, the reduction was modest, suggesting 
that the inflammasome modestly impacted LPC-induced cell 
death. There was no difference in LDH levels in Casp11−/− 
BMDMs compared with WT BMDMs, excluding a role for 
the noncanonical inflammasome. LPC treatment of Il1b−/− 
and Il18−/− cells also showed no difference from controls.
expression of nLrc4 is enhanced in the mouse cnS 
during neuroinflammation
The results in Figs. 1 and 2 revealed that NLRP3 and 
NLRC4 are important in LPC-mediated inflammasome ac-
tivation. Although NLRP3 has been studied in several neu-
rodegenerative conditions, the role of NLRC4 has not been 
extensively explored in the CNS. A previous study has shown 
that Nlrc4 RNA is expressed in mouse brain as well as in 
other tissues (Poyet et al., 2001). Because RNA expression 
does not always correlate with protein abundance, we assessed 
whether NLRC4 protein is found in the brain in the cu-
prizone model during peak inflammatory cell accumulation, 
demyelination, and mature oligodendrocyte death (Hiremath 
et al., 1998; Arnett et al., 2001). Brains of C57BL/6 mice 
that had been treated with cuprizone for 4 wk were exam-
ined for NLRC4 by immunohistochemistry (IHC) using an 
anti-NLRC4 antibody. As a specificity control, we showed 
that NLRC4 expression was detected in the brain of WT 
mice (Nlrc4+/+; 4-wk cuprizone treated) but not in identi-
cally treated Nlrc4−/− mice (Fig. 3 A). The protein was abun-
dant in astrocytes (glial fibrillary acidic protein [GFAP]+) 
and modestly abundant in microglia expressing the lectin 
Ricinus communis agglutinin 1 (RCA1+) at the corpus cal-
losum after 4 wk of cuprizone-induced demyelination in WT 
mice (Fig. 3 B). NLRC4 was not found at detectable levels 
by NeuN+ neurons and CNPase+ oligodendrocytes (Fig. S2).
nLrc4 is abundant in lesions and astrocyte-rich regions  
of human brain tissue from MS patients
To correlate clinical relevance to the cuprizone neuroinflam-
mation model, we examined human tissues with MS lesions 
and samples without MS plaques, provided by the University 
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Figure 1. the inflammasome mediates LPc-induced IL-1β secretion in mouse BMdMs. (A–D) WT, Nlrc4−/−, Nlrp3−/−, Il1b−/− (A), Asc−/− (B), Casp1−/− (C), 
and Casp11−/− (D) BMDMs were LPS primed (100 ng/ml) overnight before LPC stimulation at concentrations of 25, 50, and 100 µM for 1 h before IL-1β was 
collected from supernatants for analysis by ELI SA. (E–K) BMDMs were LPS primed (200 ng/ml) for 3 h before stimulation with 50 µM LPC in the presence 
or absence of the caspase-1 inhibitor YVAD (10 and 50 µM; E); the ROS inhibitors NAC (5 and 25 mM), MPG (1 and 2.5 mM), and APDC (10 and 50 µM; F); 
the mitochondrial ROS inhibitor Mitotempo (100 and 500 µM; G); the cathepsin B inhibitor (CA-074Me; 10 and 20 µM; H); the potassium efflux inhibitors 
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of California Los Angeles (UCLA) Human Brain and Spinal 
Fluid Resource Center (HBS FRC). The clinical synopsis of 
three controls and three MS samples used for this study is listed 
in Table 1. Three individuals were diagnosed with chronic ac-
tive MS and exhibited demyelination, with two having gliosis. 
Normal control brain tissues were devoid of inflammatory 
lesions and did not display CNS neuropathology. The plaque 
location of samples taken from the MS brains is shown in Fig. 
S3. The three samples shown on the left were diagnosed with 
MS, whereas the samples on the right (labeled Normal) were 
not. NLRC4 expression was greatly elevated in the lesion 
associated with extensive astrogliosis as marked by GFAP as 
demonstrated in the overlay panel of anti-NLRC4 and anti- 
GFAP (Fig. 3 C). Microglial accumulation was also evident, 
although fewer RCA+ microglia cells were detected com-
pared with astrocytes (compare Fig. 3, C and D, middle), and 
the overlay of anti-NLRC4 and anti-RCA staining showed 
few NLRC4+RCA+ cells compared with NLRC4+GFAP+ 
cells (Fig. 3, C and D, right). A summary of Image J (National 
Institutes of Health) quantification is shown in Tables 2 and 3. 
The MS samples showed greatly enhanced NLRC4 protein 
levels in plaque, white matter, and, to a lesser extent, gray 
matter, whereas normal controls did not express detectable 
NLRC4 protein. Astrocytes identified by GFAP staining ex-
pressed the highest amount of NLRC4, whereas microglial 
cells identified by RCA staining also expressed the protein 
but to a lower extent. Neurons and oligodendrocytes did not 
express detectable levels. These results in human specimens 
KCl (50 and 100 mM) and glyburide (100 and 200 µM; I); or the calcium inhibitors BAP TA (10 and 20 µM), 2-APB (20 and 100 µM; J), and U73122 (2 and 
10 µM; K). Then, IL-1β was collected from supernatants for analysis by ELI SA. Each control and experimental condition was performed in triplicate. All data 
are representative of at least two independent experiments. Results are displayed as the mean ± SEM. *, P < 0.05; **, P < 0.01; unpaired Student's t test.
Figure 2. the inflammasome mediates LPc-induced IL-1β maturation in mouse BMdMs. (A–D) WT, Nlrp3−/−, Nlrc4−/−, and Il1b−/− (A), Asc−/− (B), 
Casp1−/− (C), and Casp11−/− (D) BMDMs were LPS primed (100 ng/ml) overnight before LPC stimulation (25, 50, and 100 µM). Pro–IL-1β and IL-1β in the 
supernatant (sn) or cell lysate (Cell) and pro–caspase-1 in the cell lysate were assessed by immunoblotting. β-Actin was used as the loading control. (E–I) 
BMDMs were LPS primed (200 ng/ml) for 3 h and then stimulated with 50 µM LPC in the presence or absence of the caspase-1 inhibitor YVAD (E); the ROS 
inhibitors NAC, MPG, and APDC and the mitochondrial ROS inhibitor Mitotempo (F); the cathepsin B inhibitor CA-074Me (G); the potassium efflux inhibitors 
glyburide and KCl (H); and the calcium inhibitors BAP TA, 2-APB, and U73122 (I) as used in Fig. 1. IL-1β in the supernatant was assessed by immunoblotting. 
The image in F is assembled from two sections of the same blot, and the break between these two sections is indicated by a dash line. The data are repre-
sentative of two independent experiments. w/o, without.
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agree with the findings observed in mice in the previous 
paragraph (Fig. 3, A and B; and Fig. S2).
Astrocytic nLrc4 and nLrP3 display the same specificity  
as their macrophage counterparts
The findings in the previous paragraph led us to compare 
LPC-induced inflammasome activation in macrophages and 
astrocytes. Astrocytes were isolated from day-0–2 postnatal 
pups, and purity was verified by immunocytochemistry (ICC) 
using the astrocytic marker GFAP for detection of desired as-
trocytes versus the microglial marker Iba-1 for contaminating 
microglia (Fig. 4 A). In BMDMs, NLRC4 is known to respond 
to PAMPs such as bacterial flagellin and T3SS (Ma et al., 2000; 
Franchi et al., 2006, 2010; Miao et al., 2006, 2010), whereas 
NLRP3 reacts to a plethora of activators, including ATP 
(Mariathasan et al., 2006; Duncan et al., 2007). First, we con-
firmed responses of Nlrc4−/− BMDMs to PAMP stimulation, 
finding that WT and Nlrc4−/− BMDMs produced similar levels 
of IL-1β in response to the known NLRP3 stimuli LPS + ATP, 
which should not be affected by the absence of NLRC4. As 
expected, IL-1β response to LPS and flagellin was ablated in 
the Nlrc4−/− BMDMs (Fig. 4 B). Likewise, Nlrp3−/− and WT 
BMDMs showed no statistical difference in IL-1β production 
in response to LPS and flagellin, but response to LPS + ATP was 
ablated in the absence of NLRP3 (Fig. 4 C). This confirmed 
the specificity of the NLRC4 and NLRP3 inflammasomes in 
BMDMs. Next, we assessed whether astrocytic NLRC4 dis-
played the same specificity as BMDM NLRC4 using primary 
astrocytes isolated from Nlrc4−/− and WT newborn mice (Wu 
et al., 2010). Once astrocyte purity was confirmed, astrocytes 
were pretreated with LPS and transfected with S. typhimurium 
flagellin, and IL-1β release was measured by ELI SA. Upon 
transfection of WT astrocytes with increasing concentrations of 
flagellin, IL-1β release increased in a dose-dependent fashion. 
In contrast, Nlrc4−/− astrocytes showed little or no increase in 
IL-1β release when transfected with increasing concentrations 
of flagellin (Fig.  4 D). As observed with Nlrp3−/− BMDMs 
(Fig. 4 C), when Nlrp3−/− astrocytes were transfected with in-
creasing amounts of flagellin, there was no difference in IL-1β 
release compared with WT astrocytes (Fig. 4 E). Again, response 
to LPS + ATP was ablated in Nlrp3−/− but not in Nlrc4−/− as-
trocytes (Fig. 4, D and E). These results show that, similar to 
BMDMs, NLRC4 in astrocytes is required for inflammasome 
activation by flagellin, whereas NLRP3 in astrocytes is required 
for the LPS + ATP response. 
Both nLrc4 and nLrP3 are required for LPc-induced IL-1β 
secretion from primary mouse astrocytes
To extend the previous findings of LPC activating the inflam-
masome in BMDMs, we next examined whether LPC can also 
activate astrocyte-derived inflammasome activity. To establish 
inflammasome activation by LPC in astrocytes, we investi-
gated whether LPC stimulation would result in the release 
of IL-1β in WT mouse astrocytes. A dose-dependent increase 
of released IL-1β resulted in WT astrocytes treated with in-
creasing concentrations of LPC. Furthermore, when WT as-
trocytes were stimulated with LPC for 4 h as compared with 
2 h, the amount of IL-1β released was enhanced (Fig. 5 A). 
This suggests that LPC acted to stimulate IL-1β release in 
astrocytes in a concentration- and time-dependent manner.
Figure 3. nLrc4 is expressed in mouse 
cnS during neuroinflammation and in 
human brain tissue from MS patients. (A) 
WT mice brains were examined for NLRC4 ex-
pression by IHC using a mouse NLRC4 antibody. 
NLRC4 expression (red) was detected after 4 
wk of cuprizone-induced demyelination in WT 
(Nlrc4+/+) but not in Nlrc4−/− mice. (B) The cor-
pus callosum from 4-wk cuprizone–treated WT 
mice was stained with anti-NLRC4 (top, green; 
bottom, red), and RCA (red) was used to detect 
microglia (top), and GFAP (green) was used 
to detect astrocytes (bottom) at the corpus 
callosum. DAPI (blue) was used to label nu-
clei. Overlay (yellow) indicates colocalization 
of NLRC4 with the cell-specific biomarkers. 
(C and D) Chronic MS brain tissues were ob-
tained from the UCLA HBS FRC. The corpus cal-
losum sections were stained for NLRC4 using 
a human NLRC4 antibody (αNLRC4), as this 
is the region studied in the cuprizone model. 
Astrocytes (C) and microglia (D) were detected 
using GFAP and RCA antibodies. The overlay 
was performed to detect colocalization of pro-
teins. All data are representative of at least two 
independent experiments. Bars, 50 µM
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Next, we investigated whether NLRC4 mediated LPC 
stimulation of inflammasome activation. Upon 4 h of LPC 
stimulation, the IL-1β released from Nlrc4−/− astrocytes was 
attenuated compared with WT astrocytes (Fig. 5 B). Addition-
ally, Nlrp3−/− astrocytes also showed reduced IL-1β release in 
response to LPC (Fig. 5 C). The adapter protein of NLRP3 and 
NLRC4 inflammasome ASC was also required for LPC-in-
duced IL-1β production in mouse astrocytes (Fig. 5 D). These 
data agree with the data generated in BMDMs. This indi-
cates that, in contrast to the flagellin-activated inflammasome, 
which only requires NLRC4, and the ATP-induced inflam-
masome, which only requires NLRP3, LPC-induced inflam-
masome requires both NLRC4 and NLRP3.
the inflammasome mediates LPc-induced  
IL-1β secretion in microglia
The NLRP3 inflammasome has been suggested to mediate 
IL-1β secretion in microglia in neurodegenerative diseases such 
as Alzheimer’s disease and Parkinson’s disease and in response 
to neuropathology-associated markers such as α-synuclein and 
β-amyloid (Rock et al., 2010; Codolo et al., 2013; Freeman and 
Ting, 2016). Next, we examined whether LPC induces IL-1β 
release in microglia and whether this process is dependent on 
the inflammasome. Microglia were isolated using CD11b-pos-
itive selection. ICC (Fig. 6, A and B) was used to assess the 
separation of microglia (Iba-1+ cells) from GFAP+ astrocytes 
before and after CD11b selection. Microglia were isolated from 
brains of WT, Nlrc4−/−, Nlrp3−/−, Il1b−/− (Fig.  6 C), Asc−/− 
(Fig. 6 D), Casp1−/− (Fig. 6 E), Casp11−/− (Fig. 6 F), and Il18−/− 
(Fig. 6 G) neonatal mice (postnatal day 3–5). Once microglial 
purity was confirmed, microglial cells were LPS primed and 
stimulated with LPC at increasing concentrations (20, 25, and 
50 µM). As expected, there was an increase in IL-1β secretion 
in response to LPC stimulation of WT microglia, but Nlrc4−/−, 
Nlrp3−/−, Il1b−/−, Asc−/−, and Casp1−/− microglia showed sig-
nificantly attenuated IL-1β secretion compared with WT mi-
croglia. Casp11−/− and Il18−/− samples did not differ from WT 
controls. These results suggest that NLRC4, NLRP3, caspase-1, 
and the adapter protein ASC play a critical role in mediating 
LPC-induced IL-1β secretion in microglia, whereas IL-18 and 
caspase-11 are not involved.
To determine whether the inflammasome mediates py-
roptosis in microglia upon LPC treatment, we isolated mi-
croglia from WT and inflammasome-deficient mice. These 
cells were LPS primed and stimulated with LPC, and su-
pernatants were collected to measure LDH levels (Fig. S4). 
Although LDH levels were detectable in both WT and 
inflammasome-deficient microglia, there was no signifi-
cant difference among any of the canonical or noncanon-
ical inflammasome-deficient microglia (Nlrc4−/−, Nlrp3−/−, 
Asc−/−, Casp1−/−, Il1b−/−, Il18−/−, Casp1−/−, and Casp11−/−) 
compared with WT microglia, suggesting that the inflam-
masome and noncanonical inflammasome do not enhance 
LPC-induced microglial death.
the inflammasome promotes microglial 
accumulation and astrogliosis
The in vitro system indicates that NLRC4 and NLRP3 in 
astrocytes and microglia mediate inflammasome activation by 
Table 1. MS patients: clinical synopsis
Patient no. Sample no. Gender/age Clinical diagnosis Lesion type
1 HSB-2407     F/58 Normal Control
2 HSB-2803     M/92 Dementiaa Control
3 HSB-3119     F/77 MS diagnosed but not supported by neuropathological diagnosis Control
4 HSB-3391     F/48 MS; periventricular white matter shows variable demyelination, associated with prominent gliosis 
and perivascular lymphocytic and macrophage infiltration
Chronic Active 
MS
5 HSB-3442     F/63 Irregular bilateral periventricular demyelination Chronic MS
6 HSB-3704     F/47 Extensive white matter demyelination and axonal loss, perivascular lymphocytic cuffing, and 
extensive gliosis associated with areas of neuronal loss
Chronic Active 
MS
The clinical pathology of MS and control brain tissues obtained from the UCLA HBS FRC is described. Each brain was evaluated by neuropathologists at UCLA. Brain tissue from three MS cases 
was examined along with three control brains from cases without MS. In all cases, the tissue was taken from the region around or at the corpus callosum, as shown in Fig. S2.
aDementia with no distinctive pathology.
Table 2. distribution of reactivity for nLrc4 in MS lesions
Ab MS brain Control brain
Plaque Adjacent 
white matter
Adjacent gray 
matter
NAWM NAGM
NLRC4 39.585 28.714 1.511 0 0
Immunofluorescence indicating NLRC4 presence in tissue sections was quantified by 
National Institutes of Health ImageJ software (Schneider et al., 2012). The images were 
unstacked. Each image was split into channels, the threshold was set, and then the signal 
was measured. The numbers represent mean values from the output results. Abbreviations 
used: Ab, antibody; NAGM, normal-appearing gray matter; NAWM, normal-appearing 
white matter.
Table 3. cellular distribution of reactivity for nLrc4 
Ab Cellular distribution
Astrocytes 
(GFAP)
Microglia/ 
Macrophages (RCA)
Oligodendrocytes 
(O4)
Neurons 
(NeuN)
NLRC4 23.085 12.1 0 0
Immunofluorescence indicating NLRC4 presence in various cell types present in the MS 
lesions was quantified by ImageJ software. The images were unstacked. Each image was 
split into channels, the threshold was set, and then the signal was measured. The numbers 
represent mean values from the output results table generated by Image J. Ab, antibody.
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LPC. In parallel with the in vitro studies, we also assessed 
whether NLRP3 and NLRC4 play a role in the cuprizone 
model of neuroinflammation. This model consists of feeding 
mice with chow supplemented with the neurotoxicant cupri-
zone (0.2%), which results in a CNS disease model comprised 
of astrogliosis and microglial activation followed by oligoden-
drocyte cell death and demyelination.
To explore whether the NLRC4 and NLRP3 in-
flammasomes have a role during cuprizone-induced neu-
roinflammation, we examined microglial accumulation in 
WT (control), Nlrc4−/−, Nlrp3−/−, and double KO (DKO) 
Nlrp3−/−Nlrc4−/− mice (Fig. 7 A). Microglial cells are res-
ident immune cells of the CNS that release cytokines and 
chemokines and also phagocytose dead cells, cellular debris, 
and invading pathogens (Hanisch and Kettenmann, 2007; 
Napoli and Neumann, 2009). The microglia populations 
at the corpus callosum were quantified by RCA-1 lectin 
staining (Fig.  7  C). Among the untreated groups (indi-
cated as 0 wk), age-matched WT, Nlrc4−/−, Nlrp3−/−, and 
Nlrp3−/−Nlrc4−/− mice showed no difference in numbers 
of microglia at the corpus callosum, indicating that dele-
tion of Nlrc4 and/or Nlrp3 did not affect microglial ac-
cumulation in nondiseased mice at steady state (Fig. 7 C). 
After 3-wk cuprizone treatment, there was a significant re-
duction in microglial accumulation in Nlrc4−/−, Nlrp3−/−, 
and Nlrp3−/−Nlrc4−/− mice compared with WT controls 
(Fig. 7 C), with the DKO showing the most significant re-
duction. These results indicate that NLRC4 and NLRP3 
contribute to microglia accumulation at the corpus callo-
sum during demyelination.
Figure 4. Astrocytic nLrc4 and nLrP3 
display the same inflammasome specific-
ity as macrophage nLrs. (A) Immunocy-
tochemical detection of GFAP (green)- but 
not Iba-1(red)–stained cells from a purified 
mouse astrocyte culture used in Fig.  4 (D 
and E). DAPI (blue) was used to label nuclei. 
Representative images from the experiment 
performed in triplicate are shown. Bar,16 µM. 
(B) WT and Nlrc4−/− BMDMs were LPS primed 
(400 ng/ml) for 4 h and transfected with the 
transfecting reagent DOT AP and 25, 50, or 
100 ng of S. typhimurium flagellin for 1  h 
before IL-1β was collected from supernatant. 
WT and Nlrc4−/− LPS-primed BMDMs were 
also stimulated with 5 mM ATP, as a positive 
control for inflammasome activation. Cells 
were transfected with DOT AP alone or stim-
ulated with flagellin alone without LPS as a 
negative control. Data are representative of 
two independent experiments. (C) WT and 
Nlrp3−/− BMDMs were similarly treated as in 
B. Data are representative of two indepen-
dent experiments. (D) WT and Nlrc4−/− primary 
mouse astrocytes were LPS primed (400 ng/ml) 
for 4 h and transfected with 50, 100, or 200 
ng flagellin for 1 h before IL-1β was collected 
from supernatant. LPS-primed primary mouse 
WT and Nlrc4−/− astrocytes were also stimu-
lated with 5 mM ATP, as a positive control, and 
transfected with DOT AP alone or stimulated 
with flagellin alone as a negative control. Data 
are representative of three independent ex-
periments. (E) WT and Nlrp3−/− primary mouse 
astrocytes were similarly treated as described 
in D. Data are representative of two indepen-
dent experiments. (D and E) 9–12 mouse pups 
(0–2 d old) per genotype were used for each 
experiment. Each control and experimental 
condition was performed in triplicate. Results 
are displayed as the mean ± SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; 
unpaired Student’s t test.
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Next, we examined astrogliosis in WT, Nlrc4−/−, 
Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mice (Fig. 7 B). The astro-
cyte population at the corpus callosum was studied using 
GFAP staining as a marker of astrocyte activation. Among the 
control untreated groups (0 wk), age-matched WT, Nlrc4−/−, 
Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mice showed no difference 
in the number of astrocytes at the corpus callosum (Fig. 7 D), 
indicating that the basal level of astrocytes is unaffected by 
deletion of Nlrc4 and/or Nlrp3. After 3 wk of cuprizone 
treatment, there was a reduction of astrocytes in Nlrc4−/− and 
Nlrp3−/− compared with WT mice, although the difference 
did not reach significance. In contrast, there was a signifi-
cant reduction of astrocytes in Nlrp3−/−Nlrc4−/− DKO mice 
(Fig. 7 D). These results indicate that NLRC4 and NLRP3 
exacerbate astrogliosis in the CNS during demyelination.
the inflammasome promotes demyelination in mice
In the cuprizone model, overt loss of myelination follows astro-
gliosis and microglial accumulation (Matsushima and Morell, 
2001). To assess whether NLRC4 and NLRP3 play a role in 
demyelination, WT, Nlrc4−/−, Nlrp3−/−, and Nlrp3−/−Nlrc4−/− 
mice were treated with cuprizone. Representative scoring of 
the extent of demyelination was measured by Luxol Fast blue 
(LFB) staining for myelin (Fig. 8 A). Slides were read by a 
reader blinded to the identity of tissues using a scale of 0 (no 
demyelination) to 3 (complete demyelination), and demye-
lination was quantified (Fig. 8 B). Cuprizone-treated (3 wk) 
WT, Nlrc4−/−, Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mice showed 
increased demyelination at the corpus callosum (denoted by 
the purple, bracketed area; Fig. 8 A) compared with untreated 
(0 wk) WT, Nlrc4−/−, Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mice. 
3-wk cuprizone–treated Nlrc4−/− and Nlrp3−/− mice showed 
demyelination scores lower than WT mice, although the dif-
ference did not reach significance. In contrast, there was a 
significant reduction of demyelination in Nlrp3−/−Nlrc4−/− 
mice. This suggests that, in addition to promoting microglial 
accumulation and astrogliosis, NLRC4 and NLRP3 cooper-
ate to enhance demyelination.
the inflammasome-intact mice have 
elevated G2A expression
The results thus far indicate that LPC has a proinflamma-
tory effect on microglia, astrocytes, and BMDMs and that 
the inflammasome mediates LPC-induced IL-1β secretion in 
all three cell types (Fig. 1, Fig. 5, and Fig. 6, C–G). The re-
sults also demonstrate that the NLRP3 and NLRC4 inflam-
masomes exacerbate microglial accumulation and astrogliosis 
in vivo. Directly assessing LPC in the brain during cuprizone 
treatment proved to be technically difficult, with inconsistent 
results obtained. Alternately, we examined the expression of 
an LPC receptor, namely G2A, a G-protein–coupled receptor 
(GPR132) that is known to trigger release of cyclic adenosine 
monophosphate and intracellular Ca2+ to promote apopto-
sis and chemotaxis of macrophages, monocytes, and microg-
lia upon binding to LPC (Rikitake et al., 2002; Lin and Ye, 
2003). To determine whether G2A expression was detectable 
during the course of neuroinflammation caused by cupri-
zone treatment, we examined brains from mice subjected to 
4-wk cuprizone treatment. G2A expression was confirmed in 
cuprizone-treated WT brains (Fig. 9 A). Brain sections from 
WT, Nlrc4−/−, Nlrp3−/−, and Nlrp3−/−Nlrc4−/− DKO mice 
were stained for the presence of G2A (denoted by black arrows) 
Figure 5. nLrc4 and nLrP3 mediate LPc-induced 
IL-1β secretion from primary mouse astrocytes. (A) WT 
astrocytes were LPS primed (1 µg/ml) for 3 h and incubated 
with 50 and 100 µM LPC for 2 or 4 h, as indicated, before 
IL-1β was collected from the supernatant for analysis by ELI 
SA. Data are representative of three independent experiments. 
(B) WT and Nlrc4−/− astrocytes were treated as described in 
A and assayed for IL-1β secretion at 4 h. Data are represen-
tative of three independent experiments. (C and D) WT and 
Nlrp3−/− astrocytes (C) or WT and Asc−/− astrocytes (D) were 
treated as described in A and assayed for IL-1β secretion at 
4 h. Data are representative of two independent experiments. 
Each experimental condition was performed in duplicate, and 
9–12 mouse pups (0–2 d old) per genotype were used for each 
experiment. Results are displayed as the mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001; unpaired Student's t test.
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with hematoxylin used as a counter stain (Fig. 9 B). Quanti-
fication of G2A staining in untreated and cuprizone-treated 
brains was performed (Fig.  9  C). Untreated (0 wk) brains 
from WT, Nlrc4−/−, Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mice 
showed low levels of G2A expression, with no statistical dif-
ferences among these genotypes. Brains isolated from cupri-
zone-treated Nlrp3−/− and Nlrc4−/− mice showed a reduction 
in G2A+ cells, but the difference did not reach significance 
when compared with cuprizone-treated WT brains, whereas 
G2A in the brains of cuprizone-treated Nlrp3−/−Nlrc4−/− 
DKO mice showed a significant reduction. These data suggest 
that both NLRP3 and NLRC4 are required for elevated G2A 
expression under a neuroinflammatory state.
As the cuprizone model represents a mouse model of 
neuroinflammation and demyelination, we assessed whether 
G2A expression was elevated in human MS tissue. The pres-
ence of G2A in brain tissues from MS patients and patients 
without MS was analyzed (Fig. 9 D). In normal brain tissue, 
Figure 6. the inflammasome mediates LPc-induced IL-1β secretion in microglia. (A and B) ICC of Iba-1 and GFAP staining of mixed glial cell cultures 
(A) and CD11b-positive selected cells (B) isolated from postnatal day-3–5 WT mouse pups indicates the degree of microglial purity. Bars, 50 µM. (C–G) WT, 
Nlrc4−/−, Nlrp3−/−, Il1b−/− (C), Asc−/− (D), Casp-1−/− (E), Casp-11−/− (F), and Il18−/− (G) microglia were LPS primed (100 ng/ml) for 3 h and stimulated with 
LPC (20, 25, and 50 µM) for 1 h. IL-1β in the cell culture supernatant was assessed by ELI SA. Data are representative of two independent experiments. 
Each experimental condition was performed in triplicate. Results are displayed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; 
unpaired Student's t test.
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G2A expression was very low to barely detectable, whereas 
G2A expression was abundant in brain tissue from MS patients. 
These data suggest that G2A is elevated in neuroinflamma-
tion-associated conditions in both human and mouse tissues.
dIScuSSIon
There is increasing evidence that inflammatory processes 
in the CNS play a large part in neurological disorders. As 
an understanding of how DAMPs activate neuroinflam-
mation is fundamental to our understanding of CNS dis-
ease etiology, this work focuses on LPC, which has been 
associated with neurodegenerative and demyelination dis-
eases. The results show that LPC serves as a DAMP that 
induces an atypical pattern of inflammasome activation 
that is dependent on both NLRP3 and NLRC4, as well as 
ASC and caspase-1. Conventionally, NLRP3 and NLRC4 
mediate inflammasome complexes of distinct and nonover-
lapping specificities (Strowig et al., 2012; Broderick et al., 
2015; Guo et al., 2015; Broz and Dixit, 2016). Recent stud-
ies with Salmonella infection indicate that both NLRP3 
and NLRC4 are involved in inflammasome activation by 
this bacteria, which actually represents a complex patho-
gen, unlike LPC (Qu et al., 2016). In addition to the in 
vitro study here, analysis of an animal model of neuroin-
flammation and demyelination shows that both NLRP3 and 
NLRC4 exacerbate disease outcome, thus providing an in 
vivo correlate for in vitro characterization. Finally, analysis 
of purified astrocyte and microglial preparations show that 
both NLRP3 and NLRC4 are required for inflammasome 
activation by LPC in these cells.
Figure 7. nLrP3 and nLrc4 promote neu-
roinflammation. (A) Representative images of 
mouse brain sections stained for the microg-
lial marker, RCA. Samples were obtained from 
cuprizone-treated WT, Nlrc4−/−, Nlrp3−/−, and 
Nlrc4−/−Nlrp3−/− mice. RCA+ (red) microglial 
cells were measured at the corpus callosum in 
brains from untreated mice (0 wk) or after 3 wk 
of cuprizone treatment. DAPI (blue) was used 
to label nuclei. Bar, 60 µM. (B) Representative 
images of brain sections stained for the astro-
cytic marker, GFAP. Samples were obtained as 
described in A. DAPI (blue) was used to detect 
nuclei. Bar, 60 µM. (C and D) Quantification of 
microglial accumulation (C) and astrogliosis 
(D) at the midline corpus callosum in the in-
dicated strains. Cell counts are averages of six 
mice per time point. Results are displayed as 
the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001; unpaired Student’s t test. ND, not 
detectable; sq, square.
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Although NLRP3 has been extensively studied, NLRC4 
is primarily studied in the context of microbial infection. 
However, Nlrc4 mRNA is detected in the adult mouse brain 
(Poyet et al., 2001), is elevated in brain tissues from Alzhei-
mer’s patients, and is shown to mediate palmitate-induced in-
flammasome activation in astrocytic cultures (Liu and Chan, 
2014). Additionally, the absence of NLRC4 reduced brain in-
jury, although this process appears to be independent of IL-1 
(Denes et al., 2015). Heightened expression of NLRC4 has 
been associated with inflammatory diseases such as Kawasaki 
disease (Ikeda et al., 2010) and atopic dermatitis (Macaluso et 
al., 2007). Using peripheral blood mononuclear cells from pa-
tients, these authors demonstrated increased gene expression 
of NLRC4 in patients relative to healthy controls, leading the 
authors to suggest a role for NLRC4 in these inflammatory 
diseases, although the direct relevance of elevated NLRC4 in 
these diseases is undefined. A direct link between NLRC4 
and inflammation has been determined for recurrent macro-
phage activation syndrome, where this disorder was associated 
with an activating NLRC4 mutation (Canna et al., 2014).
Our previous study with Nlrp3−/−, Casp1−/−, Il1β−/−, 
and Il18−/− mice in the cuprizone model showed a NL-
RP3-dependent mechanism, leading to demyelination and 
loss of mature oligodendrocytes (Jha et al., 2010). Moreover, 
our results in Nlrp3−/− mice showed that NLRP3 deficiency 
only partially delayed demyelination and neuroinflammation, 
uncovering the possible involvement of redundant NLR pro-
teins during neuroinflammation and demyelination. This pre-
vious work did not analyze the cell types that are involved in 
inflammasome activation.
The current work provides evidence that NLRC4 
is strongly expressed in astrocytes and to a lesser extent in 
microglia during neuroinflammation. Expression of glial 
NLRC4 was enhanced in the mouse brain during chronic 
stages of neuroinflammation in the cuprizone model and in 
pathological brain sections from MS patients. As the role of 
the inflammasome in astrocytes is not well understood, the 
importance of this study lies in the functional delineation of 
LPC-induced NLRC4 and NLRP3 inflammasome activation 
in astrocytes. We also show that the canonical inflammasome 
components NLRP3, NLRC4, ASC, caspase-1, and IL-1β 
mediate LPC-induced IL-1β secretion in BMDMs and mi-
croglia, whereas caspase-11, which represents the noncanoni-
cal inflammasome pathway, is not required. These data suggest 
that inflammasome activation by LPC in macrophages and 
these two glial populations occurs via indistinguishable path-
ways. The importance of NLRC4 and NLRP3 in the CNS is 
further supported by findings in the cuprizone model, where 
mice lacking individual NLR (Nlrc4−/− or Nlrp3−/−) exhib-
ited modestly reduced astrogliosis, microglial accumulation, 
and expression of the LPC cognate receptor G2A, whereas 
Nlrp3−/−Nlrc4−/− DKO mice showed the most significant 
reduction when compared with WT mice. This suggests that 
NLRP3 and NLRC4 may function in a synergistic or coop-
erative fashion during neuroinflammation.
This study also finds that astrocytes express a relatively 
high level of NLRC4. Astrocytes, the most abundant cell type 
in the CNS, are increasingly appreciated for their broad reg-
ulatory impact on CNS homeostasis and function. Astrocytes 
perform multiple and diverse roles in the CNS, including 
the maintenance of extracellular ionic balance, promotion 
of neuronal survival, formation of synapses, and maintenance 
of the blood–brain barrier (Molofsky et al., 2012). They also 
Figure 8. the inflammasome promotes demyelination. (A) Repre-
sentative images of brain sections of untreated (0 wk) and 3-wk cupri-
zone–treated WT, Nlrc4−/−, Nlrp3−/−, and Nlrc4−/−Nlrp3−/− mice stained 
for the presence of myelin at the corpus callosum (purple dashed lines) 
with LFB (blue). Bar, 50 µM. (B) Quantification of LFB-stained WT, Nlrc4−/−, 
Nlrp3−/−, and Nlrc4−/−Nlrp3−/− mice brain sections. Each circle represents 
the mean observed LFB score for one mouse. WT, Nlrc4−/−, Nlrp3−/−, and 
Nlrc4−/−Nlrp3−/− mice were scored by a blinded reader on a scale of 0 (no 
demyelination) to 3 (complete demyelination). The mean value of each 
dataset is depicted by a red line. All scoring is restricted to the midline 
corpus callosum (purple dashed lines in A). LFB scores are means of four to 
six mice per time point. Results are displayed as the mean ± SEM. **, P < 
0.01; unpaired Student’s t test.
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provide nutrients such as glucose to neurons and play a key 
role in the repair and scarring process in the brain. Activated 
astrocytes are a major contributor to neuroinflammation and 
are important for synapse formation. With respect to the 
inflammasome genes, astrocytes express the MHC class II 
transactivator (CII TA; Collawn and Benveniste, 1999; Stüve 
et al., 2002), NOD1 and NOD2, and the inflammasome 
adapter protein ASC (de Rivero Vaccari et al., 2008). How-
ever, inflammasome activity in astrocytes has not been widely 
studied, so questions of NLRC4 mediating inflammasome 
functions in astrocytes remain unanswered.
It is commonly understood in the field that different in-
flammasome NLRs display distinct specificities for agonists/
ligands. However, we initially proposed the model wherein 
NLRs may be able to mix and match, thus expanding the 
repertoire of PAMP recognition (Ting and Davis, 2005). In-
deed, a few pairs of NLRs have been found to display com-
mon specificity. For example, the NAIP2–NLRC4 complex 
physically associates with a T3SS molecule, whereas NAIP5–
NLRC4 associates with flagellin (Kofoed and Vance, 2011; 
Zhao et al., 2011; Halff et al., 2012). Although NLRP3 and 
NLRC4 display distinct specificities, they are both required 
for inflammasome activation by Salmonella (Broz et al., 2010), 
and endogenous NLRP3 and NLRC4 have been colocalized 
in cells upon Salmonella infection (Man et al., 2014). More 
recently, analysis of a mutant NLRC4 unexpectedly revealed 
Figure 9. the inflammasome elevates expres-
sion of the LPc receptor G2A. (A) Brain sec-
tions from 4-wk cuprizone–treated WT mice were 
stained for the presence of G2A at the corpus 
callosum of the brain, as indicated by black ar-
rowheads, with a hematoxylin counter stain. (Left) 
The negative control (no G2A antibody was used), 
which shows no brown staining. (Right) G2A-pos-
itive cells (brown staining as indicated by black ar-
rowheads). Bar, 20 µm. (B) Representative images 
of 0-wk and 4-wk cuprizone–treated brains from 
WT, Nlrc4−/−, Nlrp3−/−, and Nlrc4−/−Nlrp3−/− mice 
are shown. G2A-positive cells (as indicated by 
black arrowheads) are detected within the corpus 
callosum. Bar, 20 µM. (C) G2A-positive cells within 
the corpus callosum of cuprizone-treated brains of 
WT, Nlrc4−/−, Nlrp3−/−, and Nlrc4−/−Nlrp3−/− mice 
were quantified. Cell counts are means of five to 
six mice per time point. Results are displayed as 
the mean ± SEM. *, P < 0.05; unpaired Student’s 
t test. (D) IHC of G2A-positive cells within white 
matter brain tissue of normal brain and brain from 
an MS patient. (Top, left) G2A staining of brain 
section from control. (Top, right) G2A staining of 
brain sections from deceased MS patients. The 
yellow bracketed areas contain G2A-positive cells 
and are shown magnified to reveal the stained 
cells in the bottom panels. Bars, 100 µm.
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that this mutant protein can still recruit NLRP3, which then 
engages ASC to activate the inflammasome upon infection 
with S. typhimurium (Qu et al., 2016). It will be interesting 
to examine whether this mutant NLRC4 exhibits intact in-
flammasome response to LPC.
In summary, this work provides direct evidence for the 
functional importance of NLRC4 and NLRP3 in astrocytic 
and microglial inflammasome activation and, furthermore, 
shows that NLRC4 and NLRP3 mediate inflammasome ac-
tivity by a CNS-associated DAMP, namely LPC. Considering 
the expanding importance of astrocytes and microglia in neu-
rological homeostasis and disease states, these findings have 
broad implications for understanding a plethora of neurolog-
ical disorders where neuroinflammation is evident.
MAterIALS And MethodS
Mice
Nlrc4−/− mice on the C57BL/6 background were provided 
by V. Dixit (Genentech, San Francisco, CA). Nlrp3−/− mice 
backcrossed on the C57BL/6 background have been previ-
ously described (Jha et al., 2010). C57BL/6 mice were pur-
chased from The Jackson Laboratory and were maintained at 
the University of North Carolina facility. Nlrp3−/− mice were 
crossed with Nlrc4−/− mice to generate Nlrp3−/−Nlrc4−/− 
mice. Asc−/−, Casp1−/− (Casp11Tg), and Casp11−/− mice were 
originally provided by V. Dixit. Il1b−/− mice, originally pro-
vided by D. Chaplin (University of Alabama at Birmingham, 
Birmingham, AL), and Il18−/− mice (The Jackson Laboratory) 
were also used. All mice were 8–10 wk old before the start of 
treatment. All mice were allowed to acclimate to the facility 
for 1–2 wk before cuprizone treatment. C57BL/6, Nlrc4−/−, 
Nlrp3−/−, and Nlrp3−/−Nlrc4−/− mouse lines were bred and 
maintained in house. All experiments with animals were con-
ducted under protocols approved by the Institutional Animal 
Care and Use Committee at University of North Carolina 
Chapel Hill and the National Institutes of Health Guidelines 
for Animal Care and Use. All animals were housed under spe-
cific pathogen–free conditions in sterile isolated caging in 
Association for Assessment and Accreditation of Laboratory 
Animal Care–accredited facilities.
cuprizone treatment
8–10-wk-old male mice were fed 0.2% (wt/wt) cuprizone 
(oxalic bis [cyclohexylidenehydrazide]; C9012; Sigma-Al-
drich) mixed into ground chow ad libitum for 3–4 wk to 
induce progressive demyelination (Arnett et al., 2002; Franco- 
Pons et al., 2007). Untreated control mice were maintained 
on a diet of normal pellet chow.
tissue preparation
Mice were anesthetized and perfused with PBS followed by 
4% paraformaldehyde (PFA). Brains were removed, postfixed 
in PFA, and embedded in paraffin. 5-µm coronal sections 
were cut at the fornix region of the corpus callosum. For 
frozen sections, mice were perfused and postfixed as described 
previously (Arnett et al., 2001). Brains were allowed to soak 
in 30% sucrose in PBS and snap frozen on dry ice in optimal 
cutting temperature medium. 5- and 20-µm coronal sections 
were cut at the fornix region of the corpus callosum for anal-
ysis by IHC. All analyses were restricted to the midline corpus 
callosum as described previously (Plant et al., 2007).
human brain tissue samples
The MS and control tissues were obtained from the UCLA 
HBS FRC with written informed consent from all donors, 
and the use of human tissues was reviewed via expedited re-
view procedures (45 CFR 46. 110 b [2]) and approved by 
the UCLA Institutional Review Board. The clinical pathol-
ogy of patients is listed in Table  1, with material evaluated 
by neuropathologists at the UCLA HBS FRC. Brain tissues 
from three MS cases were examined along with three con-
trol brains from cases without MS. Among MS brains, three 
different samples were obtained from each brain including 
normal-appearing white matter, normal-appearing gray mat-
ter, and plaque. Considering the control brains, two samples 
were obtained from each brain including normal-appearing 
white matter and normal-appearing gray matter. In all cases, 
the tissues were taken from regions around or at the corpus 
callosum (Fig. S3). The brain samples were obtained in 4% 
PFA and subsequently embedded in paraffin and sectioned 
into 5-µm coronal sections.
histological staining
To examine demyelination, paraffin sections were rehydrated 
through a graded series of alcohol washes and stained with 
LFB (S3382; Sigma-Aldrich) as described previously (Arnett 
et al., 2002). Sections were read by a double-blinded reader 
and graded on a scale from 0 (no demyelination) to 3 (com-
plete demyelination), with higher scores indicating increased 
pathology. For detection of microglia/macrophages, sections 
were rehydrated and permeabilized with 0.1% Triton/PBS for 
20 min at room temperature (RT) and then incubated with 
RCA-1 lectin (1:500; L-1080; Vector Laboratories) at 37°C 
for 1 h. Only RCA-1+ cells with observable DAPI-stained 
nuclei were included in the quantification.
Ihc
IHC was performed on 5-µm paraffin-embedded sections 
that were deparaffinized and rehydrated through alcohols as 
described in the previous paragraph. To detect astrocytes, sec-
tions were incubated with 5% normal goat serum in 0.1% 
Triton/PBS for 20 min at RT. Subsequently, the sections were 
washed and incubated with GFAP rabbit anti–cow monoclo-
nal antibody (1:100; Z0334; Dako/Agilent Technologies) and 
goat anti–rabbit FITC-conjugated secondary antibody (1:100; 
FI-1000; Vector Laboratories). For the detection of NLRC4, 
the sections were permeabilized with 0.1% Triton/PBS for 10 
min and incubated with rabbit anti–mouse NLRC4 antibody 
(1:100; NBP2-41124; Imgenex/Novus Biologicals) overnight 
at 4°C. After washing the sections with PBS, the primary anti-
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body was detected by incubation with goat anti–rabbit Alexa 
Fluor 488–conjugated antibody (A11034; Molecular Probes/
Thermo Fisher Scientific) for 1  h at RT. Immunopositive 
cells with an observable DAPI-stained nucleus were counted 
twice with sample identities covered from reviewers. Cell 
counts were averaged for four to seven mice per time point.
G2A staining was performed on paraffin specimens 
using G2A (M-20) antibody (goat polyclonal; sc-9692; lot 
2315; Santa Cruz Biotechnology, Inc.). Antigen retrieval was 
performed with EDTA-based buffer (950-500; Discovery 
CC1), pH 8.5, for 64 min at 100◦C and then blocked with 
Rodent Decloaker (10X; RD913L; Biocare Medical) for 
1 h at RT. The samples were given a hydrogen peroxidase 
block for 8 min at RT and then incubated in the primary 
antibody (1:50 dilution) for 2 h at RT in a Tris-based di-
luent (760-212; Discovery PSS Diluent), followed by the 
secondary antibody (polyclonal rabbit anti–goat immuno-
globulin/HRP; P0160; Dako) incubation for 1 h at RT. The 
samples were treated with diaminobenzidine and Hematox-
ylin II (790-2208; Ventana) for 12 min, followed by Bluing 
Reagent (760-2037; Ventana) for 4 min. The slide staining 
was performed using a Discovery Ultra Automated IHC 
staining system (Ventana).
Icc
ICC was performed on glial cells plated on polylysine-coated 
coverslips. To detect the presence of astrocytes, coverslips were 
permeabilized with Triton X-100 for 20 min and washed 
with PBS containing 0.05% Tween 20 for 20 min. Covers-
lips were blocked with 5% normal donkey serum (D9963; 
Sigma-Aldrich) in Triton X-100 for 30 min. Coverslips were 
incubated overnight with chicken primary GFAP antibody 
(ab1334436; Abcam) in 5% normal donkey serum (0.5:1,000) 
in Triton X-100 overnight. Coverslips were washed four 
times with PBS containing 0.05% Tween 20 and blocked 
with 5% normal donkey serum for 30 min. Coverslips were 
incubated with a donkey anti–chicken Alexa Fluor 488 anti-
body (703-545-155; Jackson ImmunoResearch Laboratories, 
Inc.) at 1:500 for 1 h at RT.
To detect the presence of microglia, coverslips were per-
meabilized with Triton X-100 for 20 min and washed with 
PBS containing 0.05% Tween 20 for 20 min. Coverslips were 
blocked with 5% normal goat serum (S-1000; Vector Labora-
tories) in Triton X-100 for 30 min. Coverslips were incubated 
overnight with rabbit primary Iba-1 antibody (ab178847; 
Abcam) in 5% normal goat serum (1:100) in Triton X-100 
overnight. Coverslips were washed four times with PBS con-
taining 0.05% Tween 20 and blocked with 5% normal goat 
serum for 30 min. Coverslips were incubated with a bioti-
nylated goat anti–rabbit antibody (BA-1000; Vector Labora-
tories) in 5% normal goat serum at 1:100 for 1 h at RT. Then, 
coverslips were incubated with an avidin-conjugated Alexa 
Fluor 594 antibody (S32356; Invitrogen) at 1:500 for 1 h at 
RT. Coverslips were mounted with DAPI media (H-1200; 
Vector Laboratories) to detect the presence of nuclei.
Imaging
For imaging of IHC, microglial and astrocytic cell counts 
were taken from the midline of the corpus callosum, confined 
to images of a 0.033-mm2 area taken with a 50× oil immer-
sion objective, whereas LFB-stained images of the corpus cal-
losum were taken at a magnification of 20. For ICC, images 
of microglia and astrocytes were taken at 20×. An upright mi-
croscope (BX-40; Olympus) with a camera (Optronics) and 
Scion image acquisition software were used for taking images 
of the mouse brains at RT. The scale bar was added by Scion 
image acquisition software. An upright microscope (BX-61; 
Olympus) with bright-field, dark-field, differential interfer-
ence contrast, and epifluorescence capability with Velocity 
software (PerkinElmer), an ORCA RC camera (Hamamatsu 
Photonics), and a color camera (RET IGA 4000R; QImag-
ing) were used for imaging human brain tissue at RT. Images 
of a ruler were also taken at 50× by an upright microscope 
(BX-40) or at 20× by an upright microscope (BX-61), and 
the scale bars for Fig.  3 and Fig. S2 were generated based 
on ruler images. Immunofluorescence in tissue sections was 
quantified by the National Institutes of Health ImageJ soft-
ware (Schneider et al., 2012).
For imaging of G2A-stained sections, G2A+ cell counts 
were taken from the midline of the corpus callosum and taken 
with a 100× oil immersion objective. An inverted microscope 
(Eclipse Ts2r; Nikon) with a camera (DS-Ri2; Nikon) and 
NIS-Elements Advanced Research image acquisition software 
were used for taking images of G2A-stained mouse brains at 
RT. The scale bar was added by the image acquisition software.
Astroglial isolation and purification
Primary mouse glial cultures were generated from brains as 
described previously with slight modifications (McCarthy and 
de Vellis, 1980). Three to four brains from neonatal mice (1–2 d 
old) were used to seed each T75 flask. In brief, the tissue 
was triturated and processed with a papain dissociation sys-
tem according to the manufacturer’s instructions (LK003150; 
Worthington Biochemical Corporation). Cells obtained as a 
result of tissue processing were resuspended in DMEM con-
taining 10% FBS (Hyclone), 100 µg/ml streptomycin, and 50 
U/ml penicillin and were plated in a T75 flask. These cultures 
were maintained in a 5%-CO2 humidified incubator at 37°C 
for 2–3 wk. Media was changed every 2–3 d. Microglial cells 
growing on top of the confluent astrocyte monolayer were 
detached by shaking at 260 rpm for 3 h at 37°C. The media 
was replaced, and the cultures were placed back on shakers at 
100 rpm for 24 h at 37°C. A confluent astrocyte layer was de-
tached from the flask using 0.2 g/L EDTA in PBS (Versene; 
Gibco), and cells were counted and replated as required. 
Astrocyte purity and potential microglial contamination was 
assessed by ICC using microglial-specific antibodies (Iba-1; 
ab107159; Abcam) and astrocyte-specific antibodies (GFAP; 
130300; Thermo Fisher Scientific). A microscope (700; ZEI SS) 
with ZEN software was used for taking images of mouse glia 
at 20×. The scale bar was added using ZEN software.
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Microglial isolation and purification
Brains were obtained from postnatal day 3–5 mouse pups 
and enzymatically treated with a tissue dissociation kit 
(LK003150). Microglial cells were isolated from mixed glial 
cell populations through CD11b-positive selection (130-
093-634; magnetic-activated cell sorting; Miltenyi Biotec). 
Microglial purity was confirmed by staining for the presence 
of a microglial marker (Iba-1) and absence of an astrocyte 
marker (GFAP) in mixed glial cell cultures and cultures that 
were subjected to CD11b-positive selection.
Flagellin transfection of astrocytes
Primary glial cultures were harvested from a pool of 0–2-d-
old neonatal mouse pup brains as previously described (Mc-
Carthy and de Vellis, 1980). Then, astrocytes were replated 
in a 96-well plate at a density of 50,000 cells per well. As-
trocytes were primed with 400 ng/ml LPS (tlrl-3pelps; In-
vivoGen) in DMEM containing 10% FBS for 4  h. Before 
transfection, wells were rinsed two to three times with PBS 
to remove any serum. Then, astrocytes were DOT AP trans-
fected with S. Typhimurium flagellin (tlrl-epstfla-5; Invivo-
Gen) in serum-free DMEM media for 1 h at concentrations 
of 6.5–200 ng per well. Supernatants from each of the wells 
were collected and then measured for the mouse cytokine 
IL-1β using an ELI SA kit (OptEIA) according to the manu-
facturer’s instructions (BD).
LPS and LPc stimulation of BMdMs
BMDMs were obtained by flushing femurs of WT, Nlrp3−/−, 
Nlrc4−/−, Nlrc4−/−Nlrp3−/−, Asc−/−, Casp1−/−, Casp11−/−, 
Il18−/−, and Il1b−/− mice with DMEM containing 10% FBS 
and penicillin/streptomycin. Cells were treated with ACK lysis 
buffer. Cells were cultured with DMEM, supplemented with 
30% GM-CSF containing L929 media, 20% FBS, and penicil-
lin/streptomycin, for 5–7 d to allow cells to differentiate into 
BMDMs. Cells were plated at a density of 100,000 cells per well 
in a 96-well plate or 1,000,000 cells per well in a 6-well plate. 
BMDMs were stimulated with DMEM containing 10% FBS 
and 100 ng/ml LPS overnight. After wells were rinsed twice 
with PBS, the cells were stimulated with serum free DMEM 
containing 25, 50, or 100 µM LPC for 1 h. Cells were pelleted 
by spinning at 400 g for 5 min, and the supernatant was col-
lected and analyzed for IL-1β secretion by ELI SA and West-
ern blotting or LDH release for cell toxicity (11644793001; 
Roche). With regard to inhibitor usage, the inhibitors were 
added after LPS priming and 30 min before 50-µM LPC 
stimulation and were maintained in cell culture during LPC 
stimulation. The caspase-1 inhibitor YVAD (FMK005) was 
purchased from R&D Systems. NAC (A9165) and MPG 
(M6635) were purchased from Sigma-Aldrich. APDC (ALX-
550-178-M001), Mitotempo (ALX-430-150-M005), Ca-
074 Me (BML-PI126-0001), glyburide (BML-KC120-0005), 
BAP TA-AM (BML-CA411-0025), 2-APB (ALX-400-
045-M100), and U73122 (BML-ST391-0005) were pur-
chased from Enzo Life Sciences.
LPS and LPc stimulation of astrocytes
Astrocytes were replated at a density of 50,000 cells per well 
in a 96-well dish plate. Then, astrocytes were primed with 
1 µg/ml LPS in DMEM containing 10% FBS overnight. 
After rinsing wells with PBS two to three times, then, cells 
were stimulated with prewarmed serum-free DMEM (37°C) 
containing LPC concentrations of 50 and 100 µM for 2 and 
4 h. Supernatants from each of the wells were collected, and 
IL-1β levels were measured.
LPS and LPc stimulation of microglia
Microglia were seeded at a density of 50,000 cells per well 
in a 96-well dish plate. First, microglia were primed with 
100 ng/ml LPS in DMEM containing 10% FBS for 3  h 
before LPC stimulation. After rinsing cells with PBS, cells 
were then stimulated with prewarmed serum-free DMEM 
(37°C) containing LPC concentrations of 20, 25, and 50 µM 
for 1 h. Supernatants from each of the wells were collected 
and then assessed for mouse cytokine IL-1β or for cytotoxic-
ity by LDH release assay.
Immunoblotting
Cells were resuspended in lysis buffer (50 mM Tris, 150 mM 
NaCl, 1% Triton X-100, protease inhibitor cocktail, and 
phosphatase inhibitor cocktail, pH 7.4). Cell lysates were in-
cubated on ice for 30 min, and cell debris was pelleted by 
centrifugation at 16,000 g for 30 min at 4°C. Clear lysates 
and cell supernatants were separated by 4–16% Bis-Tris gels 
(NativePAGE Novex; Thermo Fisher Scientific) and then 
transferred onto polyvinylidene fluoride membranes (EMD 
Millipore). The membranes were blocked with 5% milk pro-
tein before probing with primary antibodies. Primary anti-
bodies included anti–IL-1β (AF-401-SP; R&D Systems), 
anti–caspase-1 (AG-20B-0044-C100; Adipogen), and anti– 
β-actin (sc-1615; HRP conjugate; Santa Cruz Biotechnology, 
Inc.). Appropriate HRP-conjugated secondary antibodies 
were used, and proteins were detected using Enhanced Che-
miluminescent reagent (Thermo Fisher Scientific).
Statistical analysis
All values are shown as mean ± SEM. Two-tailed, unpaired 
Student’s t test was used to assess statistical significance in 
Prism (5.0; GraphPad Software). In all tests, p-values of <0.05 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001) 
were considered statistically significant. All figures are repre-
sentative of at least two independent experiments.
online supplemental material
Fig. S1 shows LPC-induced toxicity in WT, Nlrc4−/−, Nlrp3−/−, 
Asc−/−, Casp1−/−, Casp11−/−, Il1b−/−, and Il18−/− BMDMs. Fig. 
S2 shows negligible expression of NLRC4 in mouse oligoden-
drocytes or neurons in vivo. Fig. S3 shows sample location and 
pathology examination of normal and MS patient brain tissues. 
Fig. S4 shows LPC-induced toxicity in WT, Nlrc4−/−, Nlrp3−/−, 
Asc−/−, Casp1−/−, Casp11−/−, Il1b−/−, and Il18−/− microglia.
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